Treatment with NVP-BEZ235 increased phosphorylation of GSK3β (S9) in VHL-deficient cells (Supplemental Fig. S1A,B) and VHL-null RCC cell lines (Supplemental Fig. S1C,D) suggesting that NVP-BEZ235 failed to inhibit AURKA expression by reliving the inhibition on GSK3β. The gene discussed is VHL; the disease is renal cell carcinoma.